The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HCM | -29.56% | -51.01% | -13.29% | +11% |
| S&P | +16.23% | +94.45% | +14.22% | +229% |
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment covers all activities related to oncology/immunology including sales, marketing, manufacturing and research and development with respect to drugs and drug candidates. The Other Ventures segment includes all other HUTCHMED businesses. The company was founded on December 18, 2000 and is headquartered in Hong Kong.
HCM earnings call for the period ending June 30, 2019.
The pricing of a secondary offering is weighing heavily on the Chinese drug stock.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
HCM earnings call for the period ending June 30, 2021.
HCM earnings call for the period ending December 31, 2020.
HCM earnings call for the period ending June 30, 2020.
HCM earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
